Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
NCT01163838
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- LDL-C must be greater or equal to 130 mg/dl
- BMI must be between 18.5 and 40 kg/m2
- History of cardiovascular or cerebrovascular event during the past year.
- Poorly controlled type 1 or type 2 diabetes mellitus
- Subjects who have taken lipid lowering therapies within the last 3 months of
screening.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Garden Grove, California
- Garden Grove, California
- Long Beach, California
- Wildomar, California
- Clearwater, Florida
- DeLand, Florida
- Miami, Florida
- Orlando, Florida
- Atlanta, Georgia
- Overland Park, Kansas
- Overland Park, Kansas
- Overland Park, Kansas
- Kansas City, Missouri
- Kansas City, Missouri
- Saint Louis, Missouri
- Raleigh, North Carolina
- Raleigh, North Carolina
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Duncansville, Pennsylvania
- Greer, South Carolina
- Kingsport, Tennessee
- Houston, Texas
- Tomball, Texas
- Orem, Utah
- Richmond, Virginia
- Kelowna, British Columbia
- Chicoutimi, Quebec
- Laval, Quebec
- Montreal, Quebec
- Sherbrooke, Quebec
- Quebec,
- Tustin, California
- Walnut Creek, California
- Clearwater, Florida
- DeLand, Florida
- Doral, Florida
- Jacksonville, Florida
- Miami, Florida
- Woodstock, Georgia
- Woodstock, Georgia
- Overland Park, Kansas
- Wichita, Kansas
- Louisville, Kentucky
- Madisonville, Kentucky
- Auburn, Maine
- North Dartmouth, Massachusetts
- Kansas City, Missouri
- Kansas City, Missouri
- Kansas City, Missouri
- Saint Louis, Missouri
- Albuquerque, New Mexico
- Raleigh, North Carolina
- Salisbury, North Carolina
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Duncansville, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Spartanburg, South Carolina
- Knoxville, Tennessee
- Knoxville, Tennessee
- Houston, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- Norfolk, Virginia
- Richmond, Virginia
- Kelowna, British Columbia
- Chicoutimi, Quebec
- Laval, Quebec
- Montreal, Quebec
- Sherbrooke, Quebec
- Quebec,
- Peoria, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Overland Park, Kansas
- Overland Park, Kansas
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia | |||
Official Title ICMJE | A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of RN316 In Healthy Adult Subjects With Hypercholesterolemia | |||
Brief Summary | The primary objective of this study is to evaluate the safety and tolerability of repeated doses of RN316 in eligible healthy volunteers. RN316 is an investigational drug that is currently being studied as a cholesterol lowering therapy. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Withdrawn | |||
Actual Enrollment ICMJE | 0 | |||
Original Estimated Enrollment ICMJE | 91 | |||
Estimated Study Completion Date ICMJE | March 2011 | |||
Estimated Primary Completion Date | March 2011 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 80 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT01163838 | |||
Other Study ID Numbers ICMJE | B1481002 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | April 2015 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |